Phase I study of anti-HER2 CAR-engineered monocytes in HER2-overexpressing solid tumors

Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, discusses the innovative advances in CAR-Mono cell therapy. Dr Abdou highlights the development of CT-0525, a next-generation anti-HER2 CAR-Mono cell therapy designed to enhance tumor targeting and reduce manufacturing time compared to earlier CAR-M therapies. CT-0525 utilizes autologous CD14+ monocytes engineered with an Ad5f35 adenoviral vector to express an anti-HER2 CAR, showing promising pre-clinical results in tumor growth control and durability. The ongoing Phase I trial (NCT06254807) aims to evaluate the feasibility, safety, and efficacy of CT-0525 in patients with HER2-overexpressing solid tumors. Early data suggest that CT-0525 is a viable and efficient treatment option with rapid manufacturing capabilities, marking a significant advancement in CAR cell therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.